




CORRECTION

Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study

Stephen Schleicher · Angela Moore · Elyse Rafal · Angelique Gagne-Henley ·
Sandra Marchese Johnson · Sunil Dhawan · Rajeev Chavda  ·
J. P. York · Baldo Sforzolini · Kate Holcomb · Glynis Ablon ·
James Del Rosso · Brigitte Dreno

Published online: January 12, 2024
© The Author(s) 2024

Correction: Dermatol Ther (Heidelb) (2023) 13:3085–3096
<https://doi.org/10.1007/s13555-023-01042-7>

Authors would like to correct below mentioned error.

Table 1 is missing a row (see below). In the Fitzpatrick skin type, there should be an

additional row after Type V reading “Type VI” with “3 (2.5%)” for the data entry.
The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s13555-023-01042-7>.

S. Schleicher
DermDox Centers for Dermatology, Sugarloaf, PA,
USA

A. Moore
Arlington Research Center, Inc, Arlington, TX, USA

E. Rafal
DermResearchCenter of New York, Inc, Stony Brook,
NY, USA

A. Gagne-Henley
Dr Angélique Gagné-Henley MD Inc, Saint-Jerome,
Canada

S. M. Johnson
Johnson Dermatology, Fort Smith, AR, USA

S. Dhawan
Center for Dermatology Clinical Research, Inc,
Fremont, CA, USA

R. Chavda (✉)
Galderma SA, Lausanne, Switzerland
e-mail: Rajeev.chavda@galderma.com

J. P. York · B. Sforzolini
Galderma Laboratories, Dallas, TX, USA

K. Holcomb
H&H Research, Metairie, LA, USA

G. Ablon
Ablon Skin Institute & Research Center, University
of California, Los Angeles, CA, USA

J. Del Rosso
JDR Research, Las Vegas, NV, USA

B. Dreno
Nantes University, CHU Nantes, France

A. Moore
Baylor University Medical Center, Dallas, TX, USA

Table 1 Patient demographics and disease characteristics

	Overall N = 121		
Mean age (years)	22.9 (5.12)		
Age groups*			
< 18 years old	19 (15.7%)		
≥ 18 years old	102 (84.3%)		
Sex			
Male	33 (27.3%)		
Female	88 (72.7%)		
Ethnicity			
Hispanic or Latino	26 (21.5%)		
Not Hispanic or Latino	95 (78.5%)		
Race			
White	97 (80.2%)		
Black or African American	9 (7.4%)		
Asian	12 (9.9%)		
Not reported	3 (2.5%)		
Fitzpatrick skin type			
Type I	7 (5.8%)		
Type II	43 (35.5%)		
Type III	31 (25.6%)		
Type IV	26 (21.5%)		
Type V	11 (9.1%)		
Type VI	3 (2.5%)		
	Trifarotene 50 µg/g N = 121	Vehicle N = 121	Bilateral difference N = 121
Baseline Investigator Scar Global Assessment, mean (SD)	2.6 (0.67)	2.6 (0.68)	0.0 (0.13)
Baseline Investigator Scar Global Assessment			
1—Almost clear	1 (0.8%)	1 (0.8%)	N/A
2—Mild	63 (52.1%)	64 (52.9%)	N/A
3—Moderate	46 (38.0%)	44 (36.4%)	N/A
4—Severe	11 (9.1%)	12 (9.9)	N/A

Table 1 continued

	Trifarotene 50 µg/g N = 121	Vehicle N = 121	Bilateral difference N = 121
Baseline Total Atrophic Acne Scar Count, mean (SD)	11.4 (6.96)	11.6 (6.85)	– 0.2 (2.71)
Baseline 2–4 mm Atrophic Acne Scar Count, mean (SD)	10.4 (6.67)	10.4 (6.68)	0.0 (2.65)
Baseline > 4 mm Atrophic Acne Scar Count, mean (SD)	1.1 (1.58)	1.2 (1.69)	– 0.1 (1.05)
Baseline Investigator Global Assessment, mean (SD)	3.1 (0.30)	3.1 (0.30)	0.0 (0.00)
Baseline Investigator Global Assessment			
3—Moderate	109 (90.1%)	109 (90.1%)	N/A
4—Severe	12 (9.9%)	12 (9.9%)	N/A
Baseline Total Lesion Count, mean (SD)	37.3 (15.18)	37.3 (16.47)	– 0.1 (5.84)
Baseline Inflammatory Lesion Count, mean (SD)	15.0 (5.43)	14.6 (5.45)	0.4 (3.24)
Baseline Non-Inflammatory Lesion Count, mean (SD)	22.2 (13.59)	22.7 (14.78)	– 0.5 (4.63)

*Patients categorized into under 18 vs 18 or older because of differing informed consent requirements

Open Access This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material

in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.